Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Apexigen Completes $20 Million Series A Venture Round

publication date: Aug 6, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Apexigen, a California antibody company with strong connections to several China pharmas, raised $20 million in Series A1 financing. Apexigen was originally formed to be the drug development arm of Epitomics, a company built around a rabbit-based platform for developing monoclonal antibodies. Two China companies – Simcere and 3SBio – have filed with the CFDA to begin clinical trials of Apexigen-discovered drugs. More details....

Stock Symbols: (NYSE: SCR) (NSDQ: SSRX)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners